BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

The most recent Phase III data from a heart failure candidate may have been underwhelming, but a look at the broader pipeline suggests the long period of drought in innovation could soon give way to...
BioCentury | Mar 10, 2020
Product Development

March 9 Quick Takes: A first for Boehringer’s Ofev; plus Cel-Sci’s COVID-19 therapy, Sinopharm, AZ, Urovant, Hengrui, Trevena, and Tetra-Shionogi

Boehringer’s Ofev approved as first therapy for lung scarring disease FDA approved Ofev nintedanib from Boehringer Ingelheim GmbH as the first therapy for chronic fibrosing interstitial lung diseases; the NDA had received Priority Review. The...
BioCentury | Sep 6, 2019
Company News

Sumitomo Dainippon to bolster pipeline via deal for women's health, urology, rare disease vants for $3B

Sumitomo Dainippon will pay $3 billion to acquire Roivant's stakes’ in five of its “vants” encompassing women's health, urology and rare diseases, propping up its pipeline as it anticipates losing U.S. market exclusivity on antipsychotic...
BioCentury | Jul 20, 2019
Emerging Company Profile

China Ophthalmology Focus eyes Asia market

...injection, for diabetic retinopathy. The company’s most advanced programs are in Phase III testing: generic ADRB1...
...Ophthalmology Focus Ltd., Hong Kong, China Lee’s Pharmaceutical Holdings Ltd. (HKSE:950), Hong Kong, China Targets ADRB1...
BioCentury | Jun 26, 2019
Company News

June 25 Company Quick Takes: Conatus restructuring; plus Almirall-Dermira, Acer, Glenmark and more

...in patients with vEDS; the company expects to respond to FDA next quarter. The cardioselective ADRB1...
...has received two complete response letters (see "Agile gets Second CRL for Twirla" ). Targets: ADRB1...
BioCentury | Jun 14, 2019
Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
BioCentury | May 28, 2019
Distillery Therapeutics

Adrenergic receptor inhibitor combo to treat stroke

DISEASE CATEGORY: Neurology INDICATION: Stroke Mouse studies suggest inhibiting ADRA1, ADRA2 and ADRB could help treat acute ischemic stroke. In two mouse models of ischemic stroke, the combination of the ADRA1 antagonist prazosin, the ADRA2...
BioCentury | Mar 29, 2019
Clinical News

Velicept's overactive bladder therapy meets in Phase IIb

Velicept said solabegron met the primary endpoint in the Phase IIb VEL-2002 trial to treat overactive bladder. The company plans to start a Phase III program of the next-generation adrenergic receptor β 3 (ADRB3) agonist...
BioCentury | Mar 19, 2019
Clinical News

Urovant shares slide on vibegron overactive bladder data

Despite hitting the co-primary endpoints for an indication in need of treatment options, Urovant's overactive bladder therapy vibegron underwhelmed investors with its latest data on Tuesday by performing only marginally better than the generic comparator...
BioCentury | Feb 15, 2019
Company News

ZappRx, Teva partner to increase patient access to specialty respiratory drugs

The Teva Respiratory LLC unit of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) gained access to a digital platform from ZappRx Inc. (Boston, Mass.) to streamline prescription of Teva’s specialty respiratory medications. Financial terms were...
Items per page:
1 - 10 of 850